vs

Side-by-side financial comparison of Keros Therapeutics, Inc. (KROS) and Sintx Technologies, Inc. (SINT). Click either name above to swap in a different company.

Keros Therapeutics, Inc. is the larger business by last-quarter revenue ($385.0K vs $290.0K, roughly 1.3× Sintx Technologies, Inc.). On growth, Sintx Technologies, Inc. posted the faster year-over-year revenue change (-46.5% vs -87.3%). Keros Therapeutics, Inc. produced more free cash flow last quarter ($106.0M vs $-2.4M). Over the past eight quarters, Keros Therapeutics, Inc.'s revenue compounded faster (593.7% CAGR vs -35.0%).

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for hematological disorders, musculoskeletal diseases and anemia, serving underserved patient groups with unmet medical needs from its core U.S. base.

Sintx Technologies, Inc. is an advanced materials company specializing in R&D and manufacturing of high-performance silicon nitride and other technical ceramic products. It serves key segments including medical implants, aerospace & defense, industrial wear components, and electric vehicle applications, with core markets across North America, Europe and Asia-Pacific.

KROS vs SINT — Head-to-Head

Bigger by revenue
KROS
KROS
1.3× larger
KROS
$385.0K
$290.0K
SINT
Growing faster (revenue YoY)
SINT
SINT
+40.8% gap
SINT
-46.5%
-87.3%
KROS
More free cash flow
KROS
KROS
$108.3M more FCF
KROS
$106.0M
$-2.4M
SINT
Faster 2-yr revenue CAGR
KROS
KROS
Annualised
KROS
593.7%
-35.0%
SINT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
KROS
KROS
SINT
SINT
Revenue
$385.0K
$290.0K
Net Profit
$-2.2M
Gross Margin
64.8%
Operating Margin
-799.3%
Net Margin
-763.8%
Revenue YoY
-87.3%
-46.5%
Net Profit YoY
49.0%
-30.7%
EPS (diluted)
$-0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KROS
KROS
SINT
SINT
Q4 25
$385.0K
$290.0K
Q3 25
$14.3M
$208.0K
Q2 25
$18.2M
$151.0K
Q1 25
$211.2M
$369.0K
Q4 24
$542.0K
Q3 24
$388.0K
$799.0K
Q2 24
$37.0K
$859.0K
Q1 24
$83.0K
$687.0K
Net Profit
KROS
KROS
SINT
SINT
Q4 25
$-2.2M
Q3 25
$-7.3M
$-3.5M
Q2 25
$-30.7M
$-2.3M
Q1 25
$148.5M
$-2.3M
Q4 24
$-1.7M
Q3 24
$-53.0M
$-6.2M
Q2 24
$-45.3M
$-2.2M
Q1 24
$-43.1M
$-886.0K
Gross Margin
KROS
KROS
SINT
SINT
Q4 25
64.8%
Q3 25
44.7%
Q2 25
37.7%
Q1 25
33.3%
Q4 24
71.6%
Q3 24
73.7%
Q2 24
73.9%
Q1 24
67.5%
Operating Margin
KROS
KROS
SINT
SINT
Q4 25
-799.3%
Q3 25
-107.9%
-1613.0%
Q2 25
-219.2%
-1764.9%
Q1 25
72.0%
-645.8%
Q4 24
-319.6%
Q3 24
-15117.8%
-802.0%
Q2 24
-136321.6%
-315.5%
Q1 24
-58413.3%
-465.4%
Net Margin
KROS
KROS
SINT
SINT
Q4 25
-763.8%
Q3 25
-51.0%
-1701.4%
Q2 25
-169.0%
-1535.1%
Q1 25
70.3%
-621.1%
Q4 24
-312.7%
Q3 24
-13648.5%
-780.9%
Q2 24
-122316.2%
-256.6%
Q1 24
-51944.6%
-129.0%
EPS (diluted)
KROS
KROS
SINT
SINT
Q4 25
$-0.50
Q3 25
$-0.18
$-3.46
Q2 25
$-0.76
$-0.91
Q1 25
$3.62
$-1.29
Q4 24
$17.04
Q3 24
$-1.41
$-6.96
Q2 24
$-1.25
$-3.61
Q1 24
$-1.21
$-21.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KROS
KROS
SINT
SINT
Cash + ST InvestmentsLiquidity on hand
$287.4M
$4.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$303.1M
$2.9M
Total Assets
$338.0M
$9.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KROS
KROS
SINT
SINT
Q4 25
$287.4M
$4.1M
Q3 25
$693.5M
$6.3M
Q2 25
$690.2M
$4.3M
Q1 25
$720.5M
$6.5M
Q4 24
$3.6M
Q3 24
$530.7M
$4.8M
Q2 24
$405.9M
$4.6M
Q1 24
$442.4M
$5.8M
Stockholders' Equity
KROS
KROS
SINT
SINT
Q4 25
$303.1M
$2.9M
Q3 25
$703.6M
$4.1M
Q2 25
$706.7M
$4.0M
Q1 25
$728.9M
$6.1M
Q4 24
$3.9M
Q3 24
$532.8M
$5.6M
Q2 24
$420.9M
$8.8M
Q1 24
$453.9M
$9.9M
Total Assets
KROS
KROS
SINT
SINT
Q4 25
$338.0M
$9.5M
Q3 25
$742.8M
$11.4M
Q2 25
$757.2M
$9.2M
Q1 25
$784.6M
$11.4M
Q4 24
$9.4M
Q3 24
$579.3M
$11.3M
Q2 24
$455.0M
$15.3M
Q1 24
$485.8M
$17.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KROS
KROS
SINT
SINT
Operating Cash FlowLast quarter
$107.5M
$-2.3M
Free Cash FlowOCF − Capex
$106.0M
$-2.4M
FCF MarginFCF / Revenue
27520.5%
-822.8%
Capex IntensityCapex / Revenue
402.9%
14.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$239.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KROS
KROS
SINT
SINT
Q4 25
$107.5M
$-2.3M
Q3 25
$3.2M
$-2.5M
Q2 25
$-29.6M
$-2.4M
Q1 25
$161.2M
$-1.3M
Q4 24
$-1.1M
Q3 24
$-30.5M
$-2.6M
Q2 24
$-39.8M
$-2.2M
Q1 24
$-44.6M
$-2.7M
Free Cash Flow
KROS
KROS
SINT
SINT
Q4 25
$106.0M
$-2.4M
Q3 25
$3.1M
$-2.6M
Q2 25
$-30.3M
Q1 25
$160.6M
$-1.4M
Q4 24
$-1.3M
Q3 24
$-30.9M
$-2.6M
Q2 24
$-40.1M
$-2.6M
Q1 24
$-45.5M
$-2.9M
FCF Margin
KROS
KROS
SINT
SINT
Q4 25
27520.5%
-822.8%
Q3 25
21.9%
-1250.5%
Q2 25
-167.0%
Q1 25
76.0%
-368.6%
Q4 24
-234.3%
Q3 24
-7960.3%
-323.0%
Q2 24
-108408.1%
-299.7%
Q1 24
-54826.5%
-423.1%
Capex Intensity
KROS
KROS
SINT
SINT
Q4 25
402.9%
14.5%
Q3 25
0.9%
40.4%
Q2 25
4.0%
0.0%
Q1 25
0.3%
16.0%
Q4 24
26.9%
Q3 24
99.5%
1.4%
Q2 24
837.8%
41.8%
Q1 24
1139.8%
25.3%
Cash Conversion
KROS
KROS
SINT
SINT
Q4 25
Q3 25
Q2 25
Q1 25
1.09×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons